PERAZ

Cefoperazone is a semisynthetic broad-spectrum cephalosporin proposed to be effective against Pseudomonas infections.

It is a third-generation antiobiotic agent and it is used in the treatment of various bacterial infections caused by susceptible organisms in the body, including respiratory tract infections, peritonitis, skin infections, endometritis, and bacterial septicemia.

While its clinical use has been discontinued in the U.S., cefoperazone is available in several European countries most commonly under the product name, Sulperazon.

Indicated for the treatment of following infections caused by susceptible bacteria: Label 1) Respiratory tract infections caused by S. pneumoniae, H. influenzae, S. aureus (penicillinase and non-penicillinase producing strains), S. pyogenes (Group A beta-hemolytic streptococci), P. aeruginosa, Klebsiella pneumoniae, E. coli, Proteus mirabilis, and Enterobacter species. 2) Peritonitis and other intra-abdominal infections caused by E. coli, P. aeruginosa, and anaerobic gram-negative bacilli (including Bacteroides fragilis ). 3) Bacterial septicemia caused by S. pneumoniae, S. agalactiae, S. aureus, Pseudomonas aeruginosa, E. coli, Klebsiella spp., Klebsiella pneumoniae, Proteus species (indole-positive and indole-negative), Clostridium spp. and anaerobic gram-positive cocci. 4).

Infections of the skin and skin structures caused by S. aureus (penicillinase and non-penicillinase producing strains), S. pyogenes, and P. aeruginosa. 5) Pelvic Inflammatory Disease, Endometritis, and Other.

Infections of the Female Genital Tract caused by N. gonorrhoeae, S. epidermidis, S. agalactiae, E. coli, Clostridium spp., Bacteroides species (including Bacteroides fragilis), and anaerobic gram-positive cocci. 6) Urinary tract infections caused by Escherichia coli and Pseudomonas aeruginosa. 7) Enterococcal.

Although cefoperazone has been shown to be clinically effective in the treatment of infections caused by enterococci in cases of peritonitis and other intra-abdominal infections, infections of the skin and skin structures, pelvic inflammatory disease, endometritis and other infections of the female genital tract, and urinary tract infections, the majority of clinical isolates of enterococci tested are not susceptible to cefoperazone but fall just at or in the intermediate zone of susceptibility, and are moderately resistant to cefoperazone.

However, in vitro susceptibility testing may not correlate directly with in vivo results.

Despite this, cefoperazone therapy has resulted in clinical cures of enterococcal infections, chiefly in polymicrobial infections.

Cefoperazone should be used in enterococcal infections with care and at doses that achieve satisfactory serum levels of cefoperazone.

Cefoperazone is a third generation cephalosporin antibiotic.

Cefoperazone exerts its bactericidal effect by inhibiting the bacterial cell wall synthesis.

D,D-transpeptidase FtsI (Escherichia coli (strain K12)) Inhibitor Penicillin-binding protein 1B (Escherichia coli (strain K12)) Inhibitor Peptidoglycan D,D-transpeptidase MrdA (Escherichia coli (strain K12)) Inhibitor + 6 more targets.

No significant quanitity of metabolites have been identified in urine.

Cefoperazone is excreted mainly in the bile.

The mean serum half-life is approximately 2.0 hours, independent of the route of administration.

Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.

View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.

Symptoms of overdose include blood in the urine, diarrhea, nausea, upper abdominal pain, and vomiting.